Immunomedics pursues breast imaging

Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, last month submitted to the European Medicines Evaluation Agency (EMEA) a regulatory application for use of its lead product, CEA-Scan, in breast imaging applications. The company believes its clinical trials have demonstrated that the monoclonal antibody-based agent correctly identifies cancer in 82% of the women studied, and in 91%, cancer was correctly ruled out. CEA-Scan is already being sold in the U.S. and Europe for the detection of colorectal cancer.